These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 207959

  • 61. Nutritional & pharmacologic management of hyperlipoproteinemia.
    Pickering JE.
    Angiology; 1982 Sep; 33(9):577-80. PubMed ID: 6957154
    [Abstract] [Full Text] [Related]

  • 62. Long-term treatment of type III hyperlipoproteinemia with clofibrate.
    Stuyt PM, Demacker PN, Van't Laar A.
    Atherosclerosis; 1981 Sep; 40(3-4):329-36. PubMed ID: 7332612
    [Abstract] [Full Text] [Related]

  • 63. [Clofibrate banned - what now? (author's transl)].
    Schwartzkopff W.
    MMW Munch Med Wochenschr; 1979 Apr 13; 121(15):529-33. PubMed ID: 108569
    [Abstract] [Full Text] [Related]

  • 64. Effect of polyenyl phosphatidyl choline on clofibrate-induced increase in LDL cholesterol.
    Schneider J, Müller R, Buberl W, Kaffarnik H, Schubotz R, Hausmann L, Mühlfellner G, Mühlfellner O.
    Eur J Clin Pharmacol; 1979 Feb 19; 15(1):15-9. PubMed ID: 217694
    [Abstract] [Full Text] [Related]

  • 65. Influence of clofibrate on blood viscosity in primary hyperlipoproteinemia.
    Arntz HR, Leonhardt H, Dreykluft HR.
    Klin Wochenschr; 1979 Jan 01; 57(1):43-7. PubMed ID: 215822
    [Abstract] [Full Text] [Related]

  • 66. Chenodeoxycholic acid therapy for hypertriglyceridaemia in men.
    Bateson MC, Maclean D, Evans JR, Bouchier IA.
    Br J Clin Pharmacol; 1978 Mar 01; 5(3):249-54. PubMed ID: 656270
    [Abstract] [Full Text] [Related]

  • 67. Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings.
    Fletcher A, Alkjaersig N, Schonfeld G, Witztum J.
    Arteriosclerosis; 1981 Mar 01; 1(3):202-9. PubMed ID: 7295193
    [Abstract] [Full Text] [Related]

  • 68. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
    Ratzmann ML, Rjasanowski I, Bruns W, Ratzmann KP.
    Exp Clin Endocrinol; 1983 Aug 01; 82(2):216-21. PubMed ID: 6354731
    [Abstract] [Full Text] [Related]

  • 69. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
    Rees ED, Hamilton RD, Kanner IF, Wasson S, Hearn T.
    Atherosclerosis; 1976 Sep 01; 24(3):537-46. PubMed ID: 788722
    [Abstract] [Full Text] [Related]

  • 70. Diurnal lipid and lipoprotein profiles in hypertriglyceridemic patients with bezafibrate and clofibrate.
    Oster P, Lang PD, Vollmar J, Schlierf G.
    Res Exp Med (Berl); 1986 Sep 01; 186(6):435-41. PubMed ID: 3823619
    [Abstract] [Full Text] [Related]

  • 71. Management of type IV hyperlipoproteinemia. Evaluation of practical clinical approaches.
    Smith LK, Luepker RV, Rothchild SS, Gillis A, Kochman L, Warbasse JR.
    Ann Intern Med; 1976 Jan 01; 84(1):22-8. PubMed ID: 1106289
    [Abstract] [Full Text] [Related]

  • 72. [Mixed hyperlipidemia resistant to ordinary dietetic and medical treatment. 30 cases].
    De Gennes JL, Turpin G, Lambrozo J, Truffert J.
    Ann Med Interne (Paris); 1975 Nov 01; 126(11):727-36. PubMed ID: 174469
    [Abstract] [Full Text] [Related]

  • 73. Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease.
    Steele P, Battock D, Genton E.
    Circulation; 1975 Sep 01; 52(3):473-6. PubMed ID: 1157247
    [Abstract] [Full Text] [Related]

  • 74. Clinical trials with gugulipid. A new hypolipidaemic agent.
    Nityanand S, Srivastava JS, Asthana OP.
    J Assoc Physicians India; 1989 May 01; 37(5):323-8. PubMed ID: 2693440
    [Abstract] [Full Text] [Related]

  • 75. Management of hypercholesterolemia: evaluation of practical clinical approaches in healthy young adults.
    Luepker RV, Smith LK, Rothchild SS, Gillis A, Kochman L, Warbasse JR.
    Am J Cardiol; 1978 Mar 01; 41(3):590-6. PubMed ID: 204183
    [Abstract] [Full Text] [Related]

  • 76. [Primary hyperlipoproteinemia. IV. Treatment].
    Ciświcka-Sznajderman M.
    Pol Arch Med Wewn; 1971 Dec 01; 47(6):589-94. PubMed ID: 5139034
    [No Abstract] [Full Text] [Related]

  • 77. Hyperlipidemic dementia.
    Heilman KM, Fisher WR.
    Arch Neurol; 1974 Jul 01; 31(1):67-8. PubMed ID: 4834546
    [No Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.